Centessa class action lawsuit filed: Johnson fistula encouraged

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Shareholder Rights Law Firm Johnson Fistula, LLP announces that a class action lawsuit has been commenced on behalf of investors in Centessa Pharmaceuticals plc (“Centessa” or the “Company”) CNTA. The Class Action is being brought on behalf of stockholders who purchased or otherwise acquired Centessa American Depository Shares (“ADS”) between May 28, 2021 and June 1, 2022 (the “Class Period”), including on, pursuant to and/or through to the IPO of the company understandable. Investors are hereby notified that they have until November 28, 2022 to request the court to appear as lead plaintiff in this lawsuit.

What actions can I take at this time? If you have suffered a loss and would like to learn more about being a lead plaintiff, please contact Jim Baker ([email protected]) via email or phone at 619-814-4471. When emailing, please include your phone number.

To participate in this promotion you can click on the following link or copy and paste it into a browser:

https://www.johnsonfistel.com/investigations/Centessa-ysg-class-action-ipo

There are no costs or obligations for you.

On or about May 28, 2021, Centessa completed its initial public offering (“IPO”) and issued 16.5 million of its ADSs to the public at an offering price of $20 per ADS.

The complaint alleges that the offering documents were negligently prepared and, as a result, contained untrue statements about material facts or failed to state other facts necessary for the statements made not to be misleading and that they were not in accordance with the Rules and rules for their creation have been drawn up . In addition, during the Class Period, the Defendants made materially false and misleading statements about the Company’s business, operations and prospects. In particular, the Offering Documents and Defendants made false and misleading statements and/or failed to disclose the following: (i) lixivaptan was less safe than Defendants had claimed; (ii) Defendants have overstated the clinical and commercial prospects of lixivaptan; (iii) ZF874 was…


Read full story here https://www.benzinga.com/pressreleases/22/09/g29074042/centessa-class-action-complaint-filed-johnson-fistel-encourages-shareholders-to-contact-the-firm